Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
February 2014, Vol 5, No 1
February 2014, Vol 5, No 1
Adjuvant Bisphosphonates: Winner in Postmenopausal Breast Cancer
By
Phoebe Starr
SABCS 2014
February 2014, Vol 5, No 1
San Antonio, TX—Adjuvant bisphosphonates reduce the risk of bone metastases by approximately 33% and improve breast cancer–related survival by 17% in postmenopausal women with early breast cancer, according to a large meta-analysis reported at the 2013 San Antonio Breast Cancer Symposium (SABCS). Bisphosphonates had no effect on premenopausal women in the adjuvant setting.
Read Article
Aromatase Inhibitor–Related Pain Reduced with Exercise Regimen
By
Charles Bankhead
SABCS 2014
February 2014, Vol 5, No 1
San Antonio, TX—Breast cancer survivors obtained significant relief from aromatase inhibitor–associated joint pain with a prescribed exercise program, the results of a randomized clinical trial showed.
Read Article
Anastrozole Cuts the Incidence of Breast Cancer by 50% in High-Risk Women
By
Phoebe Starr
SABCS 2014
February 2014, Vol 5, No 1
San Antonio, TX—Five years of treatment with the aromatase inhibitor anastrozole (Arimidex) cut the risk of breast cancer by 50% in high-risk postmenopausal women who had not developed a first cancer.
Read Article
Aetna Announced First Patient-Centered Medical Home in Oncology
By
Jayson Slotnik, JD, MPH
Value Propositions
,
Value Peer-spectives
February 2014, Vol 5, No 1
This collaborative program is based on evidence-based decision support in cancer care, using personalized medicine and realigning payment structure with the goal of increasing patient treatment coordination, improving quality outcomes, and reducing overall costs of cancer care.
Read Article
M.D. Anderson’s Scientists Collaborate with Pfizer to Enhance Immunotherapy in Oncology
By
Jayson Slotnik, JD, MPH
Value Propositions
,
Value Peer-spectives
February 2014, Vol 5, No 1
Researchers at the University of Texas M.D. Anderson Cancer Center have announces a new collaboration with Pfizer to develop immune-based approaches to new therapies for cancer. This new effort is based on M.D. Anderson’s Moon Shots Program that aims to reduce cancer deaths significantly in the future, using the 6 moon shots that target 8 types of difficult-to-treat cancer.
Read Article
ASCO Launches Value in Cancer Care Initiative
By
Jayson Slotnik, JD, MPH
Value Propositions
,
Value Peer-spectives
February 2014, Vol 5, No 1
Responding to the relentless economic pressures on patients and oncologists and the ever-escalating costs of cancer care delivery, the American Society of Clinical Oncology (ASCO), in collaboration with the Value in Cancer Care Task Force, is developing a working definition of “value” in oncology, as well as identifying how to incorporate the implications of that approach into clinical decision-making in patient care.
Read Article
NCI Pilot Trial to Assess Value of Genetic Sequencing for Improving Patient Outcomes
By
Jayson Slotnik, JD, MPH
Value Propositions
,
Value Peer-spectives
February 2014, Vol 5, No 1
The National Cancer Institute (NCI) has launched a clinical trial to determine whether selecting therapies based on genetic mutations can improve outcomes in patients with metastatic solid tumors.
Read Article
Statin Therapy Lowers Mortality in Patients with Prostate Cancer
By
Jayson Slotnik, JD, MPH
In the Literature
February 2014, Vol 5, No 1
In a new study, researchers examined the correlation between the use of statins after a prostate cancer diagnosis and the risk of cancer-related and all-cause mortality (Yu O, et al.
J Clin Oncol
. 2014;32:5-11).
Read Article
New Gene Mutation Identified in Myeloproliferative Neoplasms
By
Jayson Slotnik, JD, MPH
In the Literature
February 2014, Vol 5, No 1
New research shows promise in deciphering the underlying mechanism of myeloproliferative neoplasms (MPNs), according to findings from a recently reported study (Klampfl T, et al.
N Engl J Med
. 2013;369:2379-2390).
Read Article
Adverse Events Reporting Suboptimal in Oncology Publications
By
Jayson Slotnik, JD, MPH
In the Literature
February 2014, Vol 5, No 1
Transparent and comprehensive reporting of AEs in published results of oncology-related clinical trials is crucial for the treatment of patients with cancer. In efforts to improve reporting of clinical trials results, the Consolidated Standards of Reporting Trials (CONSORT) extension group developed 10 recommendations in 2003 for reporting AEs. A new study of 175 publications assessed the degree to which the publication of phase 3 trials in oncology adhered with CONSORT recommendations (Sivendran S, et al.
J Clin Oncol
. 2014;32:83-89).
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma